This company listing is no longer active
CloudMD Software & Services Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for CloudMD Software & Services.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
| Healthcare winstgroei | 63.3% |
| Inkomstengroei | n/a |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | None |
| Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
CloudMD Software & Services Inc. (CVE:DOC) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 08
CloudMD Software & Services Inc.'s (CVE:DOC) 28% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Oct 21Is CloudMD Software & Services (CVE:DOC) Weighed On By Its Debt Load?
Jan 12Is Now The Time To Look At Buying CloudMD Software & Services Inc. (CVE:DOC)?
Aug 09CloudMD Software & Services Inc.'s (CVE:DOC) Intrinsic Value Is Potentially 39% Above Its Share Price
Jun 20Is CloudMD Software & Services (CVE:DOC) Using Debt In A Risky Way?
May 04Is CloudMD Software & Services (CVE:DOC) A Risky Investment?
Jan 20In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat CloudMD Software & Services onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2024 | 91 | -74 | -11 | -9 | N/A |
| 12/31/2023 | 91 | -77 | -14 | -12 | N/A |
| 9/30/2023 | 91 | -24 | -10 | -18 | N/A |
| 6/30/2023 | 92 | -108 | -7 | -13 | N/A |
| 3/31/2023 | 95 | -114 | -17 | -23 | N/A |
| 12/31/2022 | 99 | -112 | -22 | -28 | N/A |
| 9/30/2022 | 105 | -112 | -32 | -27 | N/A |
| 6/30/2022 | 111 | -28 | -40 | -36 | N/A |
| 3/31/2022 | 89 | -23 | -31 | -28 | N/A |
| 12/31/2021 | 70 | -24 | -25 | -22 | N/A |
| 9/30/2021 | 48 | -23 | -21 | -20 | N/A |
| 6/30/2021 | 22 | -21 | -14 | -13 | N/A |
| 3/31/2021 | 21 | -17 | -11 | -10 | N/A |
| 12/31/2020 | 15 | -14 | -9 | -8 | N/A |
| 9/30/2020 | 12 | -8 | -5 | -5 | N/A |
| 6/30/2020 | 10 | -7 | -3 | -3 | N/A |
| 3/31/2020 | 9 | -5 | -2 | -2 | N/A |
| 12/31/2019 | 7 | -5 | -2 | -2 | N/A |
| 9/30/2019 | 5 | -5 | -2 | -2 | N/A |
| 6/30/2019 | 3 | -5 | -3 | -3 | N/A |
| 3/31/2019 | 2 | -4 | -2 | -2 | N/A |
| 12/31/2018 | 1 | -3 | -1 | -1 | N/A |
| 9/30/2018 | 0 | -1 | -1 | -1 | N/A |
| 6/30/2018 | N/A | -1 | 0 | 0 | N/A |
| 3/31/2018 | N/A | -1 | 0 | 0 | N/A |
| 12/31/2017 | N/A | 0 | N/A | 0 | N/A |
| 9/30/2017 | 0 | 0 | N/A | 0 | N/A |
| 6/30/2017 | 0 | 0 | N/A | 0 | N/A |
| 3/31/2017 | N/A | -2 | N/A | 0 | N/A |
| 12/31/2016 | N/A | -2 | N/A | 0 | N/A |
| 9/30/2016 | 0 | -2 | N/A | 0 | N/A |
| 6/30/2016 | 0 | -2 | N/A | 0 | N/A |
| 3/31/2016 | N/A | 0 | N/A | 0 | N/A |
| 12/31/2015 | N/A | 0 | N/A | 0 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if DOC's forecast earnings growth is above the savings rate (2.1%).
Winst versus markt: Insufficient data to determine if DOC's earnings are forecast to grow faster than the Canadian market
Hoge groeiwinsten: Insufficient data to determine if DOC's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if DOC's revenue is forecast to grow faster than the Canadian market.
Hoge groei-inkomsten: Insufficient data to determine if DOC's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if DOC's Return on Equity is forecast to be high in 3 years time